Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 876 participants.
Also called NCT01708902
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 876 participants
- Registry
-
NCT01708902
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Malaysia, Philippines, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT01708902. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-04-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- linagliptin2.5mg/metformin1000mg
- Intervention (Drug)
- linagliptin2.5mg/metformin1000mg
- Intervention (Drug)
- linagliptin 5mg
- Intervention (Drug)
- Metformin 500mg
- Intervention (Drug)
- linagliptin2.5mg/metformin500mg
- Intervention (Drug)
- linagliptin2.5mg/metformin500mg
- Intervention (Drug)
- linagliptin 5mg
- Intervention (Drug)
- Metformin 1000mg
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01708902- Content hash
784c9d700bac5c697e664ef228dd31f19e4f3883ff452843eab92bbe4925457d